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Lipoprotein delivery of fatty acids and cholesterol is linked with peroxisome proliferator-activated receptor (PPAR) activation in
adipocytes and macrophages. We postulated that similar interactions exist in sebaceous epithelial cells (sebocytes) in which PPAR
activation induces diﬀerentiation. High-density lipoprotein (HDL) and very low-density lipoprotein (VLDL) markedly enhanced
sebocyte diﬀerentiation above that found with PPAR agonists and were more potent than explicable by their lipid content. The
PPARγ antagonist GW5393 reduced sebocyte diﬀerentiation to all PPAR isoform agonists, HDL and VLDL, suggesting that the
lipoprotein eﬀect ondiﬀerentiation occurs partially through activation of PPARγ. Furthermore, we found that sebocytes expressed
a unique pattern of lipogenic genes. Our results demonstrate that HDL and VLDL are the most potent inducers of sebocyte
diﬀerentiation tested to date, and these actions are partially inhibited by PPAR antagonists. This suggests that substrates provided
by lipoproteins are targeted to sebocytes and aﬀect their own disposition via PPAR activation.
1.Introduction
Sebaceous epithelial cell (sebocyte) diﬀerentiation is deﬁned
by increasing accumulation of lipid droplets, the major com-
ponent of sebum. Peroxisome proliferator-activated receptor
(PPAR) isoforms, which were originally discovered because
of their key roles in adipogenesis and lipid metabolism, have
been shown to strongly stimulate sebocyte diﬀerentiation
in vitro [1–4]. All PPAR isoforms have been identiﬁed in
sebocytes [1, 2, 5]. PPARγ seems essential for sebocyte
diﬀerentiation, as sebocytes do not appear to develop from
celllineagesdevoidofPPARγ [6],andPPARγ agonistsinduce
lipid-droplet forming colonies (LFCs) in the primary rat
preputial cell culture model of sebocyte diﬀerentiation but
not in cultured epidermal cells (keratinocytes) [1]. PPARδ
has been deduced to be important in sebocyte diﬀerentiation
since linoleic acid and carbaprostacyclin (cPGI2), which are
agonists of both PPARα and PPARδ,i n d u c em o r eL F C s
in sebocytes than either PPARα or PPARγ agonists [1].
Linoleic acid is the most eﬀective stimulator of sebocyte
diﬀerentiation tested thus far [1, 2], but its physiological
relevance is suspect since its action requires a relatively high
concentration (10−4 M), and it inappropriately stimulates
LFCs in epidermal cells [1], which raises the possibility that
it mainly acts as a fatty acid substrate for lipogenesis.
Recently, PPAR action in macrophages and adipocytes
has been shown to be intimately linked with lipopro-
tein delivery of fatty acids and cholesterol [7–14]. The
relationship is complex, and the actions of PPAR isoforms
maybeinteractive.Forexample,whilemacrophageuptakeof
low-density lipoprotein (LDL)-derived fatty acid metabolites
is PPARδ-inducible [13], it is PPARγ-dependent [7–9],
yet very low-density lipoprotein (VLDL)-induced triglyc-
eride accumulation in macrophages is absolutely PPARδ-
dependent [14]. Lipoprotein is among the lipogenic regula-
tors shown to be important for sebaceous diﬀerentiation in
studies of genetically modiﬁed mice [15].
These considerations led us to test the hypothesis that
lipoproteins interact with PPARγ and PPARδ to induce
sebocyte diﬀerentiation in a unique pattern that is related
to a distinctive pattern of gene expression. Our studies are
compatible with the concept that lipoproteins act to target
lipid substrates within skin to sebocytes, where they induce
diﬀerentiation via PPAR-mediated lipogenic pathways.2 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
2.MaterialandMethods
Cell Preparations and Culture. All animal experimentation
was conducted in accordance with accepted standards of
humane animal care. Single-cell suspensions of rat preputial
sebocytes (or epidermal cells for control purposes) obtained
from 60d.o. male Sprague-Dawley rats were prepared by
enzymatic digestion under sterile conditions, as previ-
ously reported [16]. Single-cell suspensions were plated on
growth-arrested 3T3-J2 ﬁbroblast feeder layers in Dulbecco’s
ModiﬁedEaglesMedium(DMEM)with10%fetalcalfserum
supplemented with 10−6 M insulin, 10−10 M choleratoxin,
10−6 M cortisol, and antibiotics, as previously reported [1].
The cells were grown in primary culture in 95% air/5%
CO2 at 37◦C. A serum-free chemically deﬁned cell culture
medium(CellgroComplete)wassubstitutedforDMEMplus
serum after the 3rd day of culture. Treatments were added in
triplicate for 48 hours on day 7 (preconﬂuence). Treatments
included the PPAR activators troglitazone (Tro; speciﬁc acti-
vator of PPARγ), cPGI2 (activator of PPARδ, α), and linoleic
acid(activatorofPPARδ,α).Inaddition,weusedthespeciﬁc
PPARδ agonists GW610742 (GW742) [17], and L-165041
[18], the speciﬁc PPARγ agonist GW347845 (GW845) [19],
the speciﬁc PPARγ competitive antagonist GW5393 [17]
and the noncompetitive PPARγ binding pocket antagonist
GW9662 [20] that were kindly provided by GlaxoSmith-
Kline and Merck, courtesy of Drs. Tim Willson and Joel
Berger, respectively. Agonists and antagonists were prepared
as a stock solution at 10mM in DMSO and stored in aliquots
at−20◦C.Theantagonistswereaddedtoincubationmedium
2 hours before agonists. Human lipoproteins were purchased
from EMD Biosciences. For histochemical determination
of sebocyte diﬀerentiation, cells were grown in 35mm 6-
well plates. For RNA preparations, Trizol reagent was either
added directly to single-cell suspensions or to cultured cells
attached to the plate.
Histological Analysis of Lipid Droplet Formation.L F C s
were quantiﬁed by light microscopy after Oil Red O staining,
as previously described [21]. A LFC is deﬁned as a colony
containing over 5 cells positive for Oil Red O staining (cells
equivalent to at least middiﬀerentiation of sebocytes), in
order to clearly distinguish speciﬁc cytoplasmic staining
from the amorphous staining of deteriorating cells, as pre-
viously described [1].
Triglyceride/Cholesterol Assays. Triplicate wells from
selected treatments were washed in Dulbecco’s phosphate-
buﬀered saline (PBS) three times and then trypsinized,
collected, and resuspended in PBS. The cell suspensions
were analyzed for triglyceride and cholesterol content. A UV
method for the determination of triglycerides was used
according to the manufacturer (Test-Combination Glycerol,
Roche). In a series of enzymatic reactions, NADPH was
determined by means of its light absorbance at 340nm
and was directly related to the amount of glycerol or
triglycerides present in the cell suspension. The cholesterol
content was determined by a colorimetric method (Test-
Combination Cholesterol, Roche) utilizing cholesterol oxi-
dase and reagents that generate a lutidine-dye, that is, stoi-
chiometric to the amount of cholesterol in the sample and
was measured at 405nm. Standard curves were generated for
each experiment to determine the accuracy of the assay.
Reverse Transcriptase Polymerase Chain Reaction.R T -
PCR was carried out as previously described [22]w i t h
minor modiﬁcations according to the manufacturer’s pro-
tocol (from SuperScript First-Strand Synthesis System for
RT-PCR, Gibco BRL). Brieﬂy, single-stranded cDNA was
synthesized from 2μg total RNA using reverse transcriptase
and random primers in 20μL. RT-PCR for lipogenic gene
expression was performed using speciﬁc primers (Table 1).
Two μl of single-stranded cDNA in a total 50μLP C R
reaction mixture was denatured for 5 min at 95◦C, then
thirty-ﬁvecyclesofPCRampliﬁcationwereperformedunder
the following conditions: 15 sec at 94◦C, 15 sec at 50◦C,
and 2 min at 72◦C, ﬁnally the samples were placed for
7m i na t7 2 ◦C. A negative control was carried out for
each pair of primers with the same procedure without
reversetranscriptase.AmpliﬁedDNAwasresolvedona1.5%
agarose gel containing 5μg/mL ethidium bromide and bands
visualized under UV light.
StatisticalAnalysis.One-wayANOVAfollowedbyFisher’s
ProtectedLeastDiﬀerencesposthoctestwasusedtocompare
the various treatments. Statistical analyses were performed
usingtheStatviewprogram;aP-value(two-tailed)<0.05was
considered statistically signiﬁcant.
3. Results
3.1. Speciﬁc PPARδ and PPARγ Agonists Induce Sebocyte
Diﬀerentiation. Recently available speciﬁc PPARδ agonists
were used to distinguish the role of PPARδ from that
of PPARα in sebocyte diﬀerentiation. We show that the
speciﬁc PPARδ agonist (GW742) exhibits a dose-response
eﬀect on sebocyte diﬀerentiation (P<0.001; Figure 1)
and is equipotent to the PPARδ, α agonist cPGI2 at 1μM.
A similar statistically signiﬁcant dose-response eﬀect on
sebocyte diﬀerentiation was found with the speciﬁc PPARδ
agonist L-165041 (data not shown). These results support a
speciﬁc role of PPARδ in sebocyte lipogenesis.
The speciﬁc PPARγ agonist (GW845) also exhibited a
dose-related eﬀect on sebocyte diﬀerentiation (P<0.01;
Figure 1). Furthermore, it was the most potent of all PPAR
isoform agonists tested. (P<0.01; Figure 1). These results
add further evidence of the importance of PPARγ activation
on sebocyte diﬀerentiation.
3.2. PPARγ Antagonists Block PPARγ and PPARδ Action
in Sebocytes. The speciﬁc PPARγ competitive antagonist
GW5393 at 1μM speciﬁcally inhibited the response to all
PPARγ agonists: the LFC responses to the lowest doses of the
potent speciﬁc PPARγ agonist (GW845) and the low potency
troglitazone were completely blocked, and those to higher
doses of GW845 were signiﬁcantly inhibited (Figure 1(a)).
As expected, LFC formation in response to the lowest dose
of the speciﬁc PPARδ agonist GW742 was not signiﬁcantly
inhibited by GW5393. However, the eﬀect of higher doses of
the PPARδ agonist and of the nonspeciﬁc PPARδ,α agonists
cPGI2andlinoleicacidwerepartlyinhibitedbyGW5393.We
interpret this as indicating that low-level PPARδ stimulationJ o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 3
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Figure 1: Comparison of sebocyte diﬀerentiation induced by PPAR agonists and lipoproteins before and after pretreatment with two PPAR
antagonists. Maximally eﬀective doses of the selective PPAR agonists troglitazone (TRO), carbaprostacyclin (cPGI2), and linoleic acid (LIN)
were used as indicated. HDL and LDL were used at 100μg protein/mL. The speciﬁc PPARδ (GW742) and PPARγ (GW845) agonists were
used at the doses indicated. The PPARγ antagonist GW5393 (a) and the PPAR binding pocket antagonist GW9662 (b) were added to the
cells at a dose of 1μg 2 hours prior to treatment with the PPAR agonists or lipoproteins on day 7 of primary culture. LFC determination was
made on day 9 of culture after ﬁxing and staining the cells with Oil Red O (ORO). Striped bars indicate colonies with 6–50 ORO-stained
cells, and solid bars those colonies with >50 ORO-stained cells. Means +/− SEMs are presented.4 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
Table 1: Primers for RT-PCR.
Primer sequence
Primer Forward (5  to 3 )R e v e r s e ( 5  -3 )
ACAT-1 5 -ATGGCTGCCCTGGCGGTTCTA-3  5 -CTACAGCTTCTCAATCAGCAC-3 
Add-1 5 -ATGGATTGCACATTTGAAGAC-3  5 -TGGTACTGTGGCCAGGATGGT-3 
Adipsin 5 -ATGCACAGCTCCGTGTACCTC-3  5 -TCAGGCCGTCACGTTAACACT-3 
aP2 5 -TGGAAACTCGTCTCCAGTGAG-3  5 -CAAATTTCAGTCCAGGGCCTC-3 
Apo-E 5 -ATGAAGGCTCTGTGGGCCCTG-3  5 -TCATTGATTTCTCCAGGGCAC-3 
CD36 5 -GCAGCTGCACCACATATCTAC-3  5 -GCTGGCTTGACCAGTATGTTG-3 
DGAT-1 5 -GCGGTTTCAGCAATTACCGTG-3  5 -ACTGGGGCATCATAGTTGAGC-3 
HSL 5 GAAACCTAGGAGACCAATTTC-3  5 -ACCTGCAAAGACGTTGGACAG-3 
Leptin 5 -ATGACATTTCACACACGCAGT-3  5 -CTAGAGGAGTAGGAGAAACGG -3 
Leptin-R 5 -ATGACGTGTCAGAAATTCTATG-3  5 -GGAAGCATTGGATCCAACACT-3 
LPL 5 -ATGGAGAGCAAAGCCCTGCTC-3  5 -CAGAGACTTGTCATGGCATTT-3 
MC5-R 5 - ATGAACTCCTCGTCTCACCTG -3  5 - TTAATACCTGCCAAGGAGCGT -3 
Scd-1 5 -ATGCCGGCCCACATGCTCCAA-3  5 -TCAGCTACTCTTGTGGCTCCC-3 
SR-B1 5 -ATCATGATTCTCATGGTGCCC-3  5 -TGGCAGCTGGTGACATCAGAG-3 
acyl-CoA:cholesterol acyltransferase type 1 (ACAT-1), adipocyte determination factor (Add-1), adipocyte fatty acid binding protein (aP2), apolipoprotein E
(ApoE), fatty acid translocase (CD-36), acyl-CoA:diacylglycerol acyltransferase type 1 (DGAT1), hormone sensitive lipase (HSL), leptin receptor (Leptin-R),
lipoprotein lipase (LPL), melanocortin 5 receptor (MC5-R), stearoyl-CoA desaturase type 1 (Scd-1), and scavenger receptor type BI (SR-B1).
induces sebocyte lipogenesis and that higher level PPARδ
stimulation of lipogenesis involves signaling via PPARγ.
The PPARγ binding pocket antagonist GW9662 com-
pletely blocked the eﬀect of the speciﬁc PPARδ agonist
GW742 at the lower doses and did not inhibit the eﬀect
of the speciﬁc PPARγ agonist GW845 at the lowest dose
(Figure 1(b)). Although GW9662 behaves as a relatively
speciﬁc PPARγ antagonist in adipocytes [20], these studies
indicate that GW9662 acts functionally as a speciﬁc inhibitor
of PPARδ in sebocytes. This suggests that the apparent cell-
speciﬁc eﬀects of GW9662 are dependent on cell-speciﬁc
expression of coregulator molecules. GW9662 inhibited the
responses to higher doses of both these agonists and to all
other PPAR activators. These data support the concept of
cooperation in the actions of PPARδ and PPARγ in sebocyte
lipogenesis.
3.3. The Lipoproteins HDL and VLDL Are Potent Induc-
ers of Sebocyte Diﬀerentiation. Since lipoproteins deliver
cholesterol and fatty acids to cells, we tested the eﬀect of
lipoproteins on sebocyte diﬀerentiation. HDL 100μgp r o -
tein/mL stimulated signiﬁcantly more sebocyte LFCs (89 ±
3% SEM; P<0.001) than any PPAR agonist (Figure 1).
VLDL 100μg protein/mL tended to induce even more LFCs
(99 ± 1%). In addition, sebocytes exhibited distinct pat-
terns of cholesterol and triglyceride accumulation following
treatment with HDL and VLDL (Figure 2). HDL stimulated
predominantly cholesterol accumulation, along with a lesser,
but signiﬁcant, triglyceride accumulation. VLDL stimulated
primarily triglyceride accumulation. These patterns of lipid
accumulation reﬂect the distinct core lipid composition of
these two lipoproteins [23]: HDL 100μg protein/ml contains
approximately 100μg lipid/mL, of which the core lipid
constitutes about half and consists of approximately 78%
cholesteryl ester and 22% triglyceride, while VLDL 100μg
protein/mL contains approximately 1000μg lipid/mL, of
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Figure 2: Triglyceride and cholesterol content of cultured sebocytes
following treatment with HDL and VLDL. HDL induced signiﬁ-
cantly greater concentrations of both triglyceride and cholesterol,
whereas VLDL induced a high level of triglyceride accumulation,
but had no signiﬁcant eﬀect on cholesterol accumulation. Triglyc-
eride (n = 5) and cholesterol (n = 6) were assayed per 3 wells.
Means +/− SEMs are shown.
which the core lipid constitutes about three-quarters and
consists of approximately 18% cholesteryl ester and 82%
triglycerides. Thus, HDL and VLDL appear to act in part by
deliveringsubstrateforlipogenesis.However,thisisprobably
receptor mediated for reasons discussed below.
3.4. Evidence that the Apoprotein Component of HDL and
VLDL Plays a Role in Sebocyte Diﬀerentiation. VLDL had
a dose-response eﬀect on sebocyte diﬀerentiation over theJ o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 5
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Figure 3: Comparison of protein versus lipid content of HDL,
VLDL, and LIN on induction of sebocyte diﬀerentiation. VLDL was
more potent than HDL in the induction of sebocyte diﬀerentiation
in terms of protein content but less potent when comparing lipid
content (n = 4). Means +/− SEMs are shown.
range 1–100μg protein/mL (Figure 3). VLDL was as eﬀective
in inducing LFCs as HDL at a comparable apoprotein dosage
of 100μg protein/mL but was less eﬀective at an equivalent
lipid concentration (100μg lipid/mL).
HDL was more eﬀective than linoleic acid at a dose
that had about 8% triglyceride content. Despite using
submaximal doses as low as 25μg protein/mL (about 25μg
lipid/mL), HDL was signiﬁcantly more potent than linoleic
acid, 200μg/ml (100μM; data not shown). VLDL was
as eﬀective in inducing LFCs as a dose of linoleic acid
that delivers approximately half the amount of fatty acid
(Figure 3). Notably, unlike linoleic acid, neither lipoprotein
signiﬁcantly stimulated LFCs in keratinocytes, suggesting
a sebocyte-speciﬁc eﬀect (data not shown). In addition,
human LDL had no signiﬁcant eﬀect on sebocyte diﬀeren-
tiation in our sebocyte culture system (data not shown).
Theseconsiderations suggestthatthe apoprotein component
oflipoproteinsplaysakeyroleinsebocytediﬀerentiationand
thatthemechanismoflipoproteinactionisnotsimplydueto
passive delivery of lipid substrate.
3.5. PPARδ and PPARγ Antagonists Attenuate Lipoprotein
Eﬀects on Sebocyte Diﬀerentiation. Both PPARγ antagonists
signiﬁcantly inhibited LFC formation in response to HDL
or VLDL (Figure 1). This suggests that not only do HDL
and VLDL deliver lipid substrate to sebocytes, but also
PPARs partially mediate the eﬀects of these lipoproteins
on induction of sebocyte diﬀerentiation. This conclusion
is supported by the ﬁnding that HDL and VLDL eﬀects
were not discernibly augmented by PPAR agonists (data
not shown), which is consistent with action via common
pathways. The data are compatible with the concept that
HDL and VLDL supply one or more critical signaling
molecules that act downstream of PPARγ action, perhaps
through the same PPARγ-independent pathways stimulated
by PPARδ.
3.6. Sebocytes Express a Unique Pattern of Lipogenic Genes.
The role of PPARs and lipoproteins in sebocyte diﬀer-
entiation suggests that the mode of molecular genetic
regulation of lipogenesis in sebocytes may be diﬀerent
in some respects from that in fat cells. Lipogenic gene
expression was therefore explored by RT-PCR (Figure 4).
Sebocytes were found to have a unique molecular ﬁngerprint
of lipogenic gene expression. Adipsin, adipocyte fatty acid
binding protein (aP2), fatty acid translocase (CD-36), and
melanocortin 5 receptor (MC5-R) were only detected in
sebocytes, not in epidermal cells. Leptin was detected in
cultured sebocytes (which are immature) to a greater extent
thaninfreshlydispersedsebocytes(whicharepredominantly
mature)orepidermalcells.Thehigherleptingeneexpression
in cultured than in freshly dispersed cells suggests that leptin
expression may be upregulated early in diﬀerentiation then
downregulated in late-diﬀerentiated sebocytes. In contrast,
MC5-R was detected in freshly dispersed sebocytes but
not in cultured sebocytes. MC5-R thus appears to be a
marker of a later stage of diﬀerentiation than is achieved in
culture since it is found only in freshly dispersed sebocytes.
Other lipogenic genes including acyl-CoA:cholesterol acyl-
transferase type 1 (ACAT-1), adipocyte determination factor
(Add-1), apolipoprotein E (ApoE), acyl-CoA:diacylglycerol
acyltransferase type 1 (DGAT1), leptin receptor, lipoprotein
lipase (LPL), stearoyl-CoA desaturase type 1 (Scd-1), and
scavenger receptor type BI (SR-B1) were expressed in both
sebaceouscellsandepidermalcellsatallstagesofmaturation.
Androgen (dihydrotestosterone) had no clear eﬀect on
expression of any gene tested.
4. Discussion
Our studies show that the lipoproteins HDL and VLDL
are the most eﬀective inducers yet reported of rat sebocyte
colony diﬀerentiation. Our results also indicate that PPARδ
plays a unique role in sebocyte diﬀerentiation. Notably,
HDL, VLDL, and PPARδ all boost lipogenesis in a seemingly
PPARγ-dependent manner. Our data are consistent with a
model in which lipoproteins speciﬁcally target lipids within
skin to sebocytes, where these lipids serve a dual role,
acting both as substrate and to generate signaling molecules
that induce diﬀerentiation via cell-speciﬁc PPAR-mediated
lipogenic pathways (Figure 5).
Lipoproteins interact with cells by binding of their
apoprotein to receptors, allowing for transport of their
constituent lipids into cells where they provide lipids both
as substrates for intracellular metabolism and as signaling
ligands for PPARs. Thus, regardless of their intracellular
function, their initial interaction involves association with
cell surface receptors, which could discriminate among
particular classes of lipoproteins. The potential importance
of this receptor interaction is suggested by the selectivity of
HDL and VLDL for sebocyte diﬀerentiation in comparison6 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
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Figure 4: Comparison of the expression of lipogenic regulatory
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PCR. Total RNA was isolated from adult rat preputial sebocytes,
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Figure 5: Feed-forward model of sebocyte diﬀerentiation. We
postulate that lipoproteins target lipid substrates within skin to
sebocytes through interactions with speciﬁc receptors. The sub-
strates in turn stimulate sebocyte diﬀerentiation by acting through
cell-speciﬁc PPARγ-mediated lipogenic pathways.
to linoleic acid, which also acts as both a lipid substrate and
a PPAR agonist, yet indiscriminately induces lipid droplet
formation in both sebocytes and keratinocytes [1]. Our data
suggest that the eﬀectiveness of the lipoproteins is due to a
regulatory eﬀect of the apoprotein moiety rather than the
simple delivery of substrates. The importance of receptor
interaction is further supported by the ﬁnding that VLDL
is at least, if not more potent than HDL when matched
for protein concentration, but less potent when presented
at similar lipid concentrations. The lack of induction of
Table 2: Comparison of eﬀects of PPAR agonists and lipoproteins
on lipid storage in adipocytes, macrophages, and sebocytes.
Substrates Adipocyte Macrophage Sebocyte
PPARγ positive negative positive
PPARδ positive/negative positive positive
LDL ? positive (oxLDL) no eﬀect
HDL ? ? positive
VLDL positive ? positive
oxLDL: oxidized low-density lipoprotein.
sebocyte diﬀerentiation by human LDL militates against
the possibility of lipoproteins passively transferring lipid to
target cells. Paradoxically, this ﬁnding is compatible with a
role for the LDLR in mediating lipoprotein action, since the
rodent LDL receptor has a much lower aﬃnity for human
LDL than it has for rodent LDL [24].
The role of PPARδ in sebocyte diﬀerentiation is unique.
Not only is PPARδ the predominant PPAR isoform in
sebocytes [25], but the speciﬁc PPARδ agonists GW742 and
L-165041 also are as potent as the previously described
PPARδ,α agonist cPGI2 and more potent than 100-fold
higher concentrations of linoleic acid. Furthermore, our
data support the concept that PPARδ stimulates lipogenesis
via both PPARγ-dependent and-independent pathways. We
found that the modest eﬀect of a low dose of the speciﬁc
PPARδ agonist GW742 could not be blocked by the speciﬁc
PPARγ antagonist GW5393 that blocked the more marked
eﬀect of high dose GW742 stimulation. This suggests that
high-dose PPARδ stimulation activates PPARγ signaling
pathways like those involved in linoleic acid action: linoleic
acid, a direct PPARδ, α agonist, functions as an indirect
PPARγ agonist in adipocytes [26] and in macrophages via its
oxidized metabolites 9- and 13-HODE [7].
Although PPARδ appears to be important in sebocyte
diﬀerentiation, the speciﬁc PPARγ agonist GW845 and
HDL and VLDL are more eﬀective inducers of sebocyte
diﬀerentiation. PPARγ signaling seems critical for the action
of both lipoproteins and all other PPAR isoform agonists,
since the speciﬁc PPARγ competitive antagonist GW5393
inhibits the eﬀects of all substantially.
The pattern of PPAR eﬀects in sebocytes diﬀers from
that in other model systems (Table 2). The PPARγ agonist
stimulation of sebocyte lipid metabolism resembles that in
fat cell (adipocyte) diﬀerentiation but is opposite to the
eﬀects on macrophages, in which PPARγ promotes lipid
eﬄux rather than lipid storage [13, 27, 28]. On the other
hand,PPARδ agoniststimulationofsebocytelipidformation
is similar to that found in the macrophage, where PPARδ
agonist induces storage of lipids derived from oxLDL and
serum [13], and contrasts to its action in adipocytes where
it has equivocal eﬀects on lipid storage and the overall net
eﬀect of promoting lipid catabolism [29].
Our studies also demonstrate that sebocytes have a char-
acteristic molecular ﬁngerprint: unlike keratinocytes, they
expressed adipsin, aP2, CD36, and MC5-R, and immature
sebocytes strongly expressed leptin, all of which play impor-
tant roles in lipogenesis. The unique expression pattern ofJ o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 7
CD-36makesitacandidatereceptortoexplainthespeciﬁcity
of HDL for promoting sebocyte lipogenesis in skin. CD-36
acts as a lipoprotein receptor and mediates the transport of
long-chain fatty acids in mature adipocytes, macrophages,
and other tissues following HDL binding [12, 30–32]. CD-
36 expression has also recently been demonstrated on the
surface of SZ95 human sebocytes where it is thought to play
a role in the transport of free fatty acids [33]. The scavenger
receptor SR-B1 acts similarly, but its skin expression pattern
is not conﬁned to sebocytes; thus it would not seem to be
a candidate for mediating the sebocyte-speciﬁc action of
lipoproteins.
This molecular ﬁngerprint further suggests that expres-
sionofauniquepatternoflipogenicgenesunderliessebocyte
diﬀerentiation. Adipsin is used by adipocytes to determine
their rate of glycerol incorporation into fatty acids [34]. aP2
is an intracellular fatty acid transport protein that appears to
play a role in intracytoplasmic fatty acid traﬃcking [35, 36]
and is induced by PPARs [13]. MC5-R, an appetite suppres-
sive hormone involved in the regulation of adipose stores,
has been identiﬁed in preputial and human sebaceous glands
[37, 38], where it mediates the augmentation of androgen
action by melanocyte stimulating hormone-α [39, 40].
Disruption of the MC5-R gene in mice results in hypoplasia
of sebaceous and preputial glands with decreased sebum
production [41]. Leptin is a hormone secreted by adipocytes
thatisakeymetabolicsatietysignalinhypothalamicappetite
control [42] and may downregulate fatty acid desaturation
[43]. MC5-R and leptin seem to be expressed at distinctly
diﬀerent time points during sebocyte diﬀerentiation. MC5-
R mRNA is expressed primarily in the highly diﬀerentiated
sebocytes of freshly dispersed sebocytes, but little if at all
in cultured (immature) sebocytes or epidermal cells. In
contrast,wefoundleptinmRNAtobeexpressedinimmature
sebocytes, but it was consistently barely detectable in mature
sebocytes and cultured and freshly dispersed epidermal cells.
Remarkably, with the exception of MC5-R, these genes
are not among the lipogenic genes previously identiﬁed
as essential for sebogenesis, all of which are expressed in
keratinocytes as well as sebocytes: ACAT-1 [44, 45], DGAT-1
[46], and Scd-1 [47, 48].
Interestingly,additionofandrogen(dihydrotestosterone)
to our culture system had no clear eﬀect on expression of
any gene tested. Whereas sebaceous gland growth has been
showntobedependentonandrogeninvivo,androgensalone
have not been shown to have a clear eﬀect on sebocyte diﬀer-
entiation in vitro [2, 4, 49]. Androgens, however, have been
shown to enhance the eﬀect of PPAR agonists on sebocyte
diﬀerentiation. Nevertheless, there is no convincing evidence
that this suﬃces to bring about complete maturation of
s e b a c e o u sc e l ld i ﬀerentiation in vitro. Consequently, the
mechanism by which androgens bring about full sebaceous
gland development is not yet fully understood.
5. Conclusions
On the basis of these studies, we propose a feed-forward
mechanism of sebocyte diﬀerentiation that operates through
PPARγ-dependent and PPARγ-independent pathways
(Figure 5). HDL and VLDL are the most potent inducers
of sebocyte diﬀerentiation and are both more eﬀective than
explicable by their lipid content, suggesting that their
apoproteins moieties mediate their eﬀects. In addition,
HDL and VLDL are selective for the induction of sebocyte
diﬀerentiation, as compared to keratinocyte diﬀerentiation.
These observations suggest the involvement of speciﬁc
lipoprotein receptors, such as CD-36, in activating signaling
pathways in a hierarchy that is speciﬁc for sebocytes. In
turn, accumulating lipids, such as linoleic acid itself, seem
to act as both substrates and agonists of PPARδ and PPARγ
to amplify multiple lipid metabolic pathways for net lipid
uptake and storage including further PPARγ-dependent
stimulation of CD36 expression [7–9, 13].
There is still much unknown about sebocyte diﬀerentia-
tion. Elucidation of the mechanism of sebocyte lipogenesis
will require a further understanding of the coordinated
function of the many requisite genes and gene products.
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